Cargando…
Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment
Since the approval of ibrutinib for relapsed/refractory mantle cell lymphoma (MCL), the treatment of this rare mature B-cell neoplasm has taken a great leap forward. Despite promising efficacy of the Bruton tyrosine kinase inhibitor, resistance arises inevitably and the underlying mechanisms remain...
Autores principales: | Fuhr, Viktoria, Vafadarnejad, Ehsan, Dietrich, Oliver, Arampatzi, Panagiota, Riedel, Angela, Saliba, Antoine-Emmanuel, Rosenwald, Andreas, Rauert-Wunderlich, Hilka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956352/ https://www.ncbi.nlm.nih.gov/pubmed/33668876 http://dx.doi.org/10.3390/ijms22052276 |
Ejemplares similares
-
CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma
por: Fuhr, Viktoria, et al.
Publicado: (2022) -
Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment
por: Rudelius, Martina, et al.
Publicado: (2018) -
CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma
por: Rauert-Wunderlich, Hilka, et al.
Publicado: (2018) -
ScRNA-seq and ST-seq in liver research
por: He, Jia, et al.
Publicado: (2023) -
scRNASequest: an ecosystem of scRNA-seq analysis, visualization, and publishing
por: Li, Kejie, et al.
Publicado: (2023)